Stock Track | Arrowhead Pharmaceuticals Soars 5.49% on Analyst Upgrades and Strategic Developments

Stock Track

11/26

Arrowhead Pharmaceuticals (ARWR) saw its stock price surge by 5.49% during intraday trading on Wednesday, driven by positive analyst sentiment and strategic developments.

Morgan Stanley raised its price target for Arrowhead Pharmaceuticals to $48 from $45, maintaining an Equal Weight rating. The adjustment reflects optimism around the company's growth prospects, particularly with the Redemplo launch and advancements in obesity treatments.

Additionally, TD Cowen analyst Joseph Thome reiterated a Buy rating on the stock, citing promising growth and strategic initiatives. These developments have bolstered investor confidence, contributing to the stock's upward movement.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1179190404"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1179190404\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1179190404?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-26 22:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1179190404","market":"us","top_or_hot":-1,"title":"Stock Track | Arrowhead Pharmaceuticals Soars 5.49% on Analyst Upgrades and Strategic Developments","media":"Stock Track","content":"<p>Arrowhead Pharmaceuticals (ARWR) saw its stock price surge by 5.49% during intraday trading on Wednesday, driven by positive analyst sentiment and strategic developments.</p><p>Morgan Stanley raised its price target for Arrowhead Pharmaceuticals to $48 from $45, maintaining an Equal Weight rating. The adjustment reflects optimism around the company's growth prospects, particularly with the Redemplo launch and advancements in obesity treatments.</p><p>Additionally, TD Cowen analyst Joseph Thome reiterated a Buy rating on the stock, citing promising growth and strategic initiatives. These developments have bolstered investor confidence, contributing to the stock's upward movement.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Arrowhead Pharmaceuticals Soars 5.49% on Analyst Upgrades and Strategic Developments</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Arrowhead Pharmaceuticals Soars 5.49% on Analyst Upgrades and Strategic Developments\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-26 22:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Arrowhead Pharmaceuticals (ARWR) saw its stock price surge by 5.49% during intraday trading on Wednesday, driven by positive analyst sentiment and strategic developments.</p><p>Morgan Stanley raised its price target for Arrowhead Pharmaceuticals to $48 from $45, maintaining an Equal Weight rating. The adjustment reflects optimism around the company's growth prospects, particularly with the Redemplo launch and advancements in obesity treatments.</p><p>Additionally, TD Cowen analyst Joseph Thome reiterated a Buy rating on the stock, citing promising growth and strategic initiatives. These developments have bolstered investor confidence, contributing to the stock's upward movement.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ARWR","symbol_name":"Arrowhead Research Corporation","start_time":0,"source_url":"","article_id":"1179190404","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1179190404","pubTimestamp":1764167902,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Arrowhead Pharmaceuticals (ARWR) saw its stock price surge by 5.49% during intraday trading on Wednesday, driven by positive analyst sentiment and strategic developments.Morgan Stanley raised its...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ARWR":"Arrowhead Research Corporation"},"translate_title":"个股追踪|Arrowhead Pharmaceuticals因分析师升级和战略发展飙升5.49%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARWR":1},"content_text":"Arrowhead Pharmaceuticals (ARWR) saw its stock price surge by 5.49% during intraday trading on Wednesday, driven by positive analyst sentiment and strategic developments.Morgan Stanley raised its price target for Arrowhead Pharmaceuticals to $48 from $45, maintaining an Equal Weight rating. The adjustment reflects optimism around the company's growth prospects, particularly with the Redemplo launch and advancements in obesity treatments.Additionally, TD Cowen analyst Joseph Thome reiterated a Buy rating on the stock, citing promising growth and strategic initiatives. These developments have bolstered investor confidence, contributing to the stock's upward movement.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}